UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 165

Sortiert nach

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

Clinical gastroenterology and hepatology, 2017-12, Vol.15 (12), p.1940-1949.e8

2017

Link zum Volltext

Verfügbarkeit prüfen

Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease

Journal of gastroenterology and hepatology, 2014-07, Vol.29 (7), p.1470-1476

2014

Link zum Volltext

Verfügbarkeit prüfen

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Hepatology international, 2020-12, Vol.14 (6), p.889-919

2020

Link zum Volltext

Verfügbarkeit prüfen

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.70-85

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison between obese and non-obese nonalcoholic fatty liver disease

Clinical and molecular hepatology, 2023-02, Vol.29 (Suppl), p.S58-S67

Chan, Wah-Kheong

2023

Link zum Volltext

Verfügbarkeit prüfen

Metabolic fatty liver syndromes: where do we stand in 2024?

Journal of gastroenterology and hepatology, 2024-04, Vol.39 (4), p.613-614

2024

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Digestive diseases and sciences, 2020-02, Vol.65 (2), p.623-631

2020

Link zum Volltext

Verfügbarkeit prüfen

Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography

Journal of gastroenterology and hepatology, 2019-08, Vol.34 (8), p.1396-1403

2019

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of Helicobacter pylori Infection and Public Health Implications

Helicobacter (Cambridge, Mass.), 2011-09, Vol.16 (s1), p.1-9

2011

Link zum Volltext

Verfügbarkeit prüfen

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Journal of viral hepatitis, 2020-12, Vol.27 (12), p.1297-1305

2020

Link zum Volltext

Verfügbarkeit prüfen

Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B

Journal of viral hepatitis, 2023-08, Vol.30 (8), p.712-712

2023

Link zum Volltext

Verfügbarkeit prüfen

Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions

Liver international, 2022-02, Vol.42 (2), p.271-273

2022

Link zum Volltext

Verfügbarkeit prüfen

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.86-98

2018

Link zum Volltext

Verfügbarkeit prüfen

Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action

Alimentary pharmacology & therapeutics, 2020-06, Vol.51 (12), p.1429-1430

2020

Link zum Volltext

Verfügbarkeit prüfen

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease

Journal of gastroenterology and hepatology, 2022-05, Vol.37 (5), p.795-811

2022

Link zum Volltext

Verfügbarkeit prüfen

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2021-08, Vol.54 (4), p.470-480

2021

Link zum Volltext

Verfügbarkeit prüfen

MACK‐3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non‐alcoholic steatohepatitis

Liver international, 2019-07, Vol.39 (7), p.1315-1324

2019

Link zum Volltext

Verfügbarkeit prüfen

Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis?

Journal of gastroenterology and hepatology, 2018-10, Vol.33 (10), p.1787-1794

2018

Link zum Volltext

Verfügbarkeit prüfen

Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?

Nephrology (Carlton, Vic.), 2023-08, Vol.28 (8), p.425-433

2023

Link zum Volltext

Verfügbarkeit prüfen

Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease

Liver international, 2020-11, Vol.40 (11), p.2719-2731

2020

Link zum Volltext

Verfügbarkeit prüfen

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease

Alimentary pharmacology & therapeutics, 2023-12, Vol.58 (11-12), p.1194-1204

2023

Link zum Volltext

Verfügbarkeit prüfen

Liver stiffness measurement in non‐alcoholic fatty liver disease: Two is better than one

Journal of gastroenterology and hepatology, 2020-08, Vol.35 (8), p.1404-1411

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(164)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(109)
Gastroenterology & Hepatology
(95)
Humans
(73)
Liver Diseases
(47)
Fatty Liver
(44)
Female
(36)
Male
(35)
Middle Aged
(34)
Biopsy
(32)
Fibrosis
(30)
Hepatology
(26)
Nafld
(23)
Gastroenterology
(22)
Non-Alcoholic Fatty Liver Disease
(22)
Non-Alcoholic Fatty Liver Disease - Diagnosis
(21)
Adult
(20)
Non-Alcoholic Fatty Liver Disease - Epidemiology
(18)
Liver
(17)
Liver - Pathology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

Comparison between obese and non-obese nonalcoholic fatty liver disease

Metabolic fatty liver syndromes: where do we stand in 2024?

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography

Epidemiology of Helicobacter pylori Infection and Public Health Implications

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B

Individual Patient Data Meta-Analysis of Controlled Attenuation Parameter (CAP) Technology for Assessing Steatosis

Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease

MACK‐3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non‐alcoholic steatohepatitis

Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis?

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study

Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?

Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease

Liver stiffness measurement in non‐alcoholic fatty liver disease: Two is better than one

Suchergebnisse filtern